{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:01:08Z","timestamp":1784656868399,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006356","name":"Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01530-x","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:23:58Z","timestamp":1784647438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Tumor DNA Sequencing for Early Diagnosis and Detection of Treatment Response, Minimal Residual Disease, and Recurrence in Gastroesophageal Cancer"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-3514","authenticated-orcid":false,"given":"Mikkel M\u00f8ller","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Venzel","family":"Rudbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bau","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben A.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"3","key":"1530_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"1530_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1530_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","volume":"111","author":"NJ Shaheen","year":"2016","unstructured":"Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett\u2019s Esophagus. Am J Gastroenterol. 2016;111(1):30\u201350. quiz 1.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1530_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"10","key":"1530_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol"},{"key":"1530_CR6","unstructured":"Danish Esophago-Gastric Cancer Database (DEGC). National Annual Report 2023\/2024. Publish June 30, 2025. Danish Health Care Quality Institute (SundK). Retrieved from: https:\/\/www.sundk.dk\/media\/rikppa5t\/decg-aarsrapport_2024_offentliggjort_version_20250630.pdf"},{"issue":"2","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2050640618811477","volume":"7","author":"E Rodr\u00edguez de Santiago","year":"2019","unstructured":"Rodr\u00edguez de Santiago E, Hernanz N, Marcos-Prieto HM, De-Jorge-Turri\u00f3n M, Barreiro-Alonso E, Rodr\u00edguez-Escaja C, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. United Eur Gastroenterol J. 2019;7(2):189\u201398.","journal-title":"United Eur Gastroenterol J"},{"issue":"5","key":"1530_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/SLA.0000000000005638","volume":"276","author":"MC Kalff","year":"2022","unstructured":"Kalff MC, Henckens SPG, Voeten DM, Heineman DJ, Hulshof M, van Laarhoven HWM, et al. Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study. Ann Surg. 2022;276(5):806\u201313.","journal-title":"Ann Surg"},{"issue":"6","key":"1530_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s10120-019-00953-9","volume":"22","author":"R Takahashi","year":"2019","unstructured":"Takahashi R, Ohashi M, Kano Y, Ida S, Kumagai K, Nunobe S, et al. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy. Gastric Cancer. 2019;22(6):1256\u201362.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1530_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-016-1042-y","volume":"14","author":"D Liu","year":"2016","unstructured":"Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14(1):305.","journal-title":"World J Surg Oncol"},{"issue":"10466","key":"1530_CR11","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang H, Wang F, Hallemeier CL, Lerut T, Fu J. Oesophageal cancer. Lancet. 2024;404(10466):1991\u20132005.","journal-title":"Lancet"},{"key":"1530_CR12","volume-title":"Digestive System Tumors. WHO classification of tumours series","author":"F Carneiro","year":"2019","unstructured":"Carneiro F, Fukayama M, Grabsch HI, Yasui W. Gastric Adenocarcinoma. In: Board WCOTE, editor. Digestive System Tumors. WHO classification of tumours series. Volume 1, 5th ed. Lyon (France): International Agency for Research on Cancer; 2019.","edition":"5"},{"issue":"7517","key":"1530_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"7636","key":"1530_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169\u201375.","journal-title":"Nature"},{"issue":"2","key":"1530_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00535-018-1508-5","volume":"54","author":"KM Koldby","year":"2019","unstructured":"Koldby KM, Mortensen MB, Detlefsen S, Pfeiffer P, Thomassen M, Kruse TA. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. J Gastroenterol. 2019;54(2):108\u201321.","journal-title":"J Gastroenterol"},{"issue":"5","key":"1530_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/14737159.2017.1308824","volume":"17","author":"MR Openshaw","year":"2017","unstructured":"Openshaw MR, Richards CJ, Guttery DS, Shaw JA, Thomas AL. The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Rev Mol Diagn. 2017;17(5):459\u201370.","journal-title":"Expert Rev Mol Diagn"},{"key":"1530_CR17","doi-asserted-by":"crossref","unstructured":"Grizzi G, Salati M, Bonomi M, Ratti M, Holladay L, De Grandis MC et al. Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives. Int J Mol Sci. 2023;24(11).","DOI":"10.3390\/ijms24119421"},{"issue":"3","key":"1530_CR18","doi-asserted-by":"publisher","first-page":"e431060","DOI":"10.1200\/EDBK_431060","volume":"44","author":"NB Balmaceda","year":"2024","unstructured":"Balmaceda NB, Petrillo A, Krishnan M, Zhao JJ, Kim S, Klute KA, et al. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. Am Soc Clin Oncol Educ Book. 2024;44(3):e431060.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1530_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12935-024-03209-4","volume":"24","author":"JH Li","year":"2024","unstructured":"Li JH, Zhang DY, Zhu JM, Dong L. Clinical applications and perspectives of circulating tumor DNA in gastric cancer. Cancer Cell Int. 2024;24(1):13.","journal-title":"Cancer Cell Int"},{"key":"1530_CR20","doi-asserted-by":"crossref","unstructured":"Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, Kolesar J et al. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med. 2019;8(3).","DOI":"10.3390\/jcm8030373"},{"key":"1530_CR21","doi-asserted-by":"publisher","first-page":"749250","DOI":"10.3389\/fmed.2021.749250","volume":"8","author":"M Chivu-Economescu","year":"2021","unstructured":"Chivu-Economescu M, Necula L, Matei L, Dragu D, Bleotu C, Diaconu CC. Clinical Applications of Liquid Biopsy in Gastric Cancer. Front Med (Lausanne). 2021;8:749250.","journal-title":"Front Med (Lausanne)"},{"issue":"112","key":"1530_CR22","first-page":"2166","volume":"58","author":"Y Li","year":"2011","unstructured":"Li Y, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011;58(112):2166\u201370.","journal-title":"Hepatogastroenterology"},{"key":"1530_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fonc.2018.00275","volume":"8","author":"H Saluja","year":"2018","unstructured":"Saluja H, Karapetis CS, Pedersen SK, Young GP, Symonds EL. The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. Front Oncol. 2018;8:275.","journal-title":"Front Oncol"},{"issue":"3\u20134","key":"1530_CR24","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel P, Metais P. [Nuclear Acids In Human Blood Plasma]. C R Seances Soc Biol Fil. 1948;142(3\u20134):241\u20133.","journal-title":"C R Seances Soc Biol Fil"},{"key":"1530_CR25","first-page":"1","volume":"42","author":"OB Alese","year":"2022","unstructured":"Alese OB, Cook N, Ortega-Franco A, Ulanja MB, Tan L, Tie J. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. Am Soc Clin Oncol Educ Book. 2022;42:1\u201320.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1530_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","volume":"22","author":"S Ma","year":"2023","unstructured":"Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023;22(1):7.","journal-title":"Mol Cancer"},{"issue":"4","key":"1530_CR27","first-page":"1659","volume":"61","author":"S Jahr","year":"2001","unstructured":"Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659\u201365.","journal-title":"Cancer Res"},{"issue":"1","key":"1530_CR28","first-page":"67","volume":"3","author":"GD Sorenson","year":"1994","unstructured":"Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67\u201371.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1530_CR29","doi-asserted-by":"crossref","unstructured":"Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466).","DOI":"10.1126\/scitranslmed.aat4921"},{"key":"1530_CR30","doi-asserted-by":"crossref","unstructured":"Labiano I, Huerta AE, Arrazubi V, Hernandez-Garcia I, Mata E, Gomez D et al. State of the Art: ctDNA in Upper Gastrointestinal Malignancies. Cancers (Basel). 2023;15(5).","DOI":"10.3390\/cancers15051379"},{"key":"1530_CR31","first-page":"e934106","volume":"28","author":"J Min","year":"2022","unstructured":"Min J, Zhou H, Jiang S, Yu H. A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer. Med Sci Monit. 2022;28:e934106.","journal-title":"Med Sci Monit"},{"key":"1530_CR32","doi-asserted-by":"crossref","unstructured":"Mencel J, Slater S, Cartwright E, Starling N. The Role of ctDNA in Gastric Cancer. Cancers (Basel). 2022;14(20).","DOI":"10.3390\/cancers14205105"},{"issue":"8","key":"1530_CR33","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.12727","volume":"14","author":"HT Chan","year":"2020","unstructured":"Chan HT, Nagayama S, Chin YM, Otaki M, Hayashi R, Kiyotani K, et al. Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Mol Oncol. 2020;14(8):1719\u201330.","journal-title":"Mol Oncol"},{"key":"1530_CR34","doi-asserted-by":"publisher","first-page":"107458","DOI":"10.1016\/j.pharmthera.2019.107458","volume":"207","author":"A Campos-Carrillo","year":"2020","unstructured":"Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2020;207:107458.","journal-title":"Pharmacol Ther"},{"issue":"10409","key":"1530_CR35","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag D, Beer TM, McDonnell CH 3rd, Nadauld L, Dilaveri CA, Reid R, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251\u201360.","journal-title":"Lancet"},{"issue":"8","key":"1530_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","volume":"22","author":"D Chakravarty","year":"2021","unstructured":"Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet. 2021;22(8):483\u2013501.","journal-title":"Nat Rev Genet"},{"issue":"6378","key":"1530_CR37","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926\u201330.","journal-title":"Science"},{"issue":"9","key":"1530_CR38","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1073\/pnas.1910041117","volume":"117","author":"C Douville","year":"2020","unstructured":"Douville C, Cohen JD, Ptak J, Popoli M, Schaefer J, Silliman N, et al. Assessing aneuploidy with repetitive element sequencing. Proc Natl Acad Sci U S A. 2020;117(9):4858\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7761","key":"1530_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385\u20139.","journal-title":"Nature"},{"issue":"738","key":"1530_CR40","doi-asserted-by":"publisher","first-page":"eadj9283","DOI":"10.1126\/scitranslmed.adj9283","volume":"16","author":"AV Annapragada","year":"2024","unstructured":"Annapragada AV, Niknafs N, White JR, Bruhm DC, Cherry C, Medina JE, et al. Genome-wide repeat landscapes in cancer and cell-free DNA. Sci Transl Med. 2024;16(738):eadj9283.","journal-title":"Sci Transl Med"},{"key":"1530_CR41","unstructured":"Nguyen VTC, Nguyen TH, Doan NNT, Pham TMQ, Nguyen GTH, Nguyen TD et al. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Elife. 2023;12."},{"issue":"8","key":"1530_CR42","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.xcrm.2024.101664","volume":"5","author":"Z Jiao","year":"2024","unstructured":"Jiao Z, Zhang X, Xuan Y, Shi X, Zhang Z, Yu A, et al. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma. Cell Rep Med. 2024;5(8):101664.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1530_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13073-024-01352-1","volume":"16","author":"P Yu","year":"2024","unstructured":"Yu P, Chen P, Wu M, Ding G, Bao H, Du Y, et al. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer. Genome Med. 2024;16(1):79.","journal-title":"Genome Med"},{"issue":"10500","key":"1530_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(25)01021-9","volume":"406","author":"WK Tan","year":"2025","unstructured":"Tan WK, Ross-Innes CS, Somerset T, Markert G, Markowetz F, O\u2019Donovan M, et al. Biomarker risk stratification with capsule sponge in the surveillance of Barrett\u2019s oesophagus: prospective evaluation of UK real-world implementation. Lancet. 2025;406(10500):271\u201382.","journal-title":"Lancet"},{"issue":"5","key":"1530_CR45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.suc.2015.05.009","volume":"95","author":"PF Pinsky","year":"2015","unstructured":"Pinsky PF. Principles of Cancer Screening. Surg Clin North Am. 2015;95(5):953\u201366.","journal-title":"Surg Clin North Am"},{"issue":"3","key":"1530_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.21037\/jgo.2019.01.14","volume":"10","author":"M Iqbal","year":"2019","unstructured":"Iqbal M, Roberts A, Starr J, Mody K, Kasi PM. Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. J Gastrointest Oncol. 2019;10(3):400\u20136.","journal-title":"J Gastrointest Oncol"},{"key":"1530_CR47","doi-asserted-by":"publisher","first-page":"117727192211415","DOI":"10.1177\/11772719221141525","volume":"17","author":"W He","year":"2022","unstructured":"He W, Yang J, Sun X, Jiang S, Jiang J, Liu M, et al. Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer. Biomark Insights. 2022;17:11772719221141525.","journal-title":"Biomark Insights"},{"issue":"16","key":"1530_CR48","doi-asserted-by":"publisher","first-page":"26281","DOI":"10.18632\/oncotarget.15457","volume":"8","author":"J Du","year":"2017","unstructured":"Du J, Wu X, Tong X, Wang X, Wei J, Yang Y, et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. Oncotarget. 2017;8(16):26281\u20137.","journal-title":"Oncotarget"},{"issue":"10","key":"1530_CR49","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, et al. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discov. 2019;9(10):1388\u2013405.","journal-title":"Cancer Discov"},{"key":"1530_CR50","doi-asserted-by":"crossref","unstructured":"Frigault MM, Markovets A, Nuttall B, Kim KM, Park SH, Gangolli EA et al. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer. JCO Precis Oncol. 2020;4.","DOI":"10.1200\/PO.19.00386"},{"issue":"24","key":"1530_CR51","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1158\/1078-0432.CCR-18-1128","volume":"24","author":"S Kato","year":"2018","unstructured":"Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, et al. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018;24(24):6248\u201356.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1530_CR52","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.CD-17-1260","volume":"8","author":"SB Maron","year":"2018","unstructured":"Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, et al. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8(6):696\u2013713.","journal-title":"Cancer Discov"},{"issue":"20","key":"1530_CR53","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","volume":"27","author":"T Jogo","year":"2021","unstructured":"Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, et al. Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. Clin Cancer Res. 2021;27(20):5619\u201327.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1530_CR54","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1002\/ctm2.254","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Chen Z, Chong X, Chen Y, Wang Z, Yu R, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. Clin Transl Med. 2020;10(8):e254.","journal-title":"Clin Transl Med"},{"issue":"32","key":"1530_CR55","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.23.02626","volume":"42","author":"M Yagisawa","year":"2024","unstructured":"Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, et al. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. J Clin Oncol. 2024;42(32):3817\u201325.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1530_CR56","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1038\/s41467-024-51271-3","volume":"15","author":"H Singh","year":"2024","unstructured":"Singh H, Lowder KE, Kapner K, Kelly RJ, Zheng H, McCleary NJ, et al. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2\u2009+\u2009gastroesophageal adenocarcinoma. Nat Commun. 2024;15(1):6833.","journal-title":"Nat Commun"},{"issue":"7","key":"1530_CR57","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","volume":"68","author":"DS Wang","year":"2019","unstructured":"Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68(7):1152\u201361.","journal-title":"Gut"},{"issue":"23","key":"1530_CR58","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, et al. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019;25(23):7098\u2013112.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1530_CR59","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342.","journal-title":"Nat Med"},{"issue":"4","key":"1530_CR60","first-page":"176","volume":"37","author":"DV Catenacci","year":"2023","unstructured":"Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, et al. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric\/ Gastroesophageal Adenocarcinoma. Oncol (Williston Park). 2023;37(4):176\u201383.","journal-title":"Oncol (Williston Park)"},{"issue":"18","key":"1530_CR61","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","volume":"29","author":"SB Maron","year":"2023","unstructured":"Maron SB, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, et al. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. Clin Cancer Res. 2023;29(18):3633\u201340.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1530_CR62","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1111\/1759-7714.14610","volume":"13","author":"D Yang","year":"2022","unstructured":"Yang D, Xu F, Li Y, Lai X, Xian B, Yu P, et al. Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma. Thorac Cancer. 2022;13(19):2786\u201391.","journal-title":"Thorac Cancer"},{"issue":"1","key":"1530_CR63","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1038\/s41598-023-32645-x","volume":"13","author":"C Inagaki","year":"2023","unstructured":"Inagaki C, Kawakami H, Maeda D, Sakai D, Urakawa S, Nishida K, et al. The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. Sci Rep. 2023;13(1):5652.","journal-title":"Sci Rep"},{"issue":"4","key":"1530_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3892\/mco.2024.2727","volume":"20","author":"Q He","year":"2024","unstructured":"He Q, Shi X, Yan J, Wu M, Gu C, Yu X. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second\u2013line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study. Mol Clin Oncol. 2024;20(4):29.","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"1530_CR65","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"1","key":"1530_CR66","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","volume":"19","author":"Y Jin","year":"2020","unstructured":"Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020;19(1):154.","journal-title":"Mol Cancer"},{"issue":"4","key":"1530_CR67","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/1078-0432.CCR-19-2443","volume":"26","author":"RJ Kelly","year":"2020","unstructured":"Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, et al. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020;26(4):846\u201354.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1530_CR68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3349\/ymj.2023.0096","volume":"64","author":"SH Jung","year":"2023","unstructured":"Jung SH, Lee CK, Kwon WS, Yun S, Jung M, Kim HS, et al. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy. Yonsei Med J. 2023;64(9):531\u201340.","journal-title":"Yonsei Med J"},{"issue":"1","key":"1530_CR69","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41467-024-46307-7","volume":"15","author":"B Chen","year":"2024","unstructured":"Chen B, Liu S, Zhu Y, Wang R, Cheng X, Chen B, et al. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab. Nat Commun. 2024;15(1):1919.","journal-title":"Nat Commun"},{"key":"1530_CR70","doi-asserted-by":"crossref","unstructured":"Mimura K, Ogata T, Nguyen PHD, Roy S, Kared H, Yuan YC et al. Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer. J Immunother Cancer. 2024;12(1).","DOI":"10.1136\/jitc-2023-008385"},{"issue":"11","key":"1530_CR71","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamasurg.2023.4395","volume":"158","author":"HY Ng","year":"2023","unstructured":"Ng HY, Ko JMY, Lam KO, Kwong DLW, Lo AWI, Wong IYH, et al. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma. JAMA Surg. 2023;158(11):1141\u201350.","journal-title":"JAMA Surg"},{"issue":"1","key":"1530_CR72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12967-022-03567-5","volume":"20","author":"W Xi","year":"2022","unstructured":"Xi W, Zhou C, Xu F, Sun D, Wang S, Chen Y, et al. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA. J Transl Med. 2022;20(1):365.","journal-title":"J Transl Med"},{"key":"1530_CR73","doi-asserted-by":"publisher","first-page":"e11146","DOI":"10.7717\/peerj.11146","volume":"9","author":"J Li","year":"2021","unstructured":"Li J, Li Z, Ding Y, Xu Y, Zhu X, Cao N, et al. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer. PeerJ. 2021;9:e11146.","journal-title":"PeerJ"},{"key":"1530_CR74","doi-asserted-by":"publisher","first-page":"175883592312250","DOI":"10.1177\/17588359231225038","volume":"16","author":"H Yuan","year":"2024","unstructured":"Yuan H, Xu F, Wang S, Liu D, Zhang H, Zhang J, et al. Analysis of circulating tumor DNA identifies distinct therapeutic response to intraperitoneal and intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis. Ther Adv Med Oncol. 2024;16:17588359231225038.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1530_CR75","first-page":"203","volume":"13","author":"R Wu","year":"2020","unstructured":"Wu R, Shi C, Chen Q, Wu F, Li Q. Detection of circulating tumor cell DNA for monitoring advanced gastric cancer. Int J Clin Exp Pathol. 2020;13(2):203\u201311.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"1530_CR76","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/ol.2020.12329","volume":"21","author":"R Jia","year":"2021","unstructured":"Jia R, Zhao CH, Li PS, Liu RR, Zhang Y, Chen HE, et al. Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma. Oncol Lett. 2021;21(1):68.","journal-title":"Oncol Lett"},{"issue":"1","key":"1530_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3857\/roj.2022.00444","volume":"41","author":"WK Cho","year":"2023","unstructured":"Cho WK, Lee J, Youn SM, Oh D, Lim DH, Yoon HG, et al. Liquid biopsy using cfDNA to predict radiation therapy response in solid tumors. Radiat Oncol J. 2023;41(1):32\u20139.","journal-title":"Radiat Oncol J"},{"key":"1530_CR78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2019.04.003","volume":"43","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019;43:261\u20139.","journal-title":"EBioMedicine"},{"issue":"3","key":"1530_CR79","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.currproblcancer.2020.100685","volume":"45","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, et al. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. Curr Probl Cancer. 2021;45(3):100685.","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"1530_CR80","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41467-020-14310-3","volume":"11","author":"A Leal","year":"2020","unstructured":"Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11(1):525.","journal-title":"Nat Commun"},{"issue":"6","key":"1530_CR81","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1245\/s10434-023-13194-z","volume":"30","author":"Y Morimoto","year":"2023","unstructured":"Morimoto Y, Matsuda S, Kawakubo H, Nakamura K, Kobayashi R, Hisaoka K, et al. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2023;30(6):3747\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1530_CR82","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.xcrm.2023.101349","volume":"5","author":"N Moldovan","year":"2024","unstructured":"Moldovan N, van der Pol Y, van den Ende T, Boers D, Verkuijlen S, Creemers A, et al. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis. Cell Rep Med. 2024;5(1):101349.","journal-title":"Cell Rep Med"},{"issue":"9","key":"1530_CR83","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/1878-0261.13481","volume":"17","author":"M Zhang","year":"2023","unstructured":"Zhang M, Yang H, Fu T, Meng M, Feng Y, Qu C, et al. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II\/III gastric cancer. Mol Oncol. 2023;17(9):1930\u201342.","journal-title":"Mol Oncol"},{"issue":"4","key":"1530_CR84","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30(4):1023\u201334.","journal-title":"Nat Med"},{"issue":"3","key":"1530_CR85","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/path.6175","volume":"261","author":"T van den Ende","year":"2023","unstructured":"van den Ende T, van der Pol Y, Creemers A, Moldovan N, Boers D, van Berge Henegouwen MI, et al. Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma. J Pathol. 2023;261(3):286\u201397.","journal-title":"J Pathol"},{"issue":"4","key":"1530_CR86","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2020.12.010","volume":"32","author":"E Ococks","year":"2021","unstructured":"Ococks E, Frankell AM, Masque Soler N, Grehan N, Northrop A, Coles H, et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol. 2021;32(4):522\u201332.","journal-title":"Ann Oncol"},{"issue":"1","key":"1530_CR87","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/s12885-019-6025-2","volume":"19","author":"P Meng","year":"2019","unstructured":"Meng P, Wei J, Geng Y, Chen S, Terpstra MM, Huang Q, et al. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients. BMC Cancer. 2019;19(1):818.","journal-title":"BMC Cancer"},{"issue":"38","key":"1530_CR88","doi-asserted-by":"publisher","first-page":"62280","DOI":"10.18632\/oncotarget.11409","volume":"7","author":"M Ueda","year":"2016","unstructured":"Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, et al. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget. 2016;7(38):62280\u201391.","journal-title":"Oncotarget"},{"issue":"16","key":"1530_CR89","doi-asserted-by":"publisher","first-page":"16687","DOI":"10.1002\/cam4.6286","volume":"12","author":"Z Qi","year":"2023","unstructured":"Qi Z, Li Y, Wang Z, Tan X, Zhou Y, Li Z, et al. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay. Cancer Med. 2023;12(16):16687\u201396.","journal-title":"Cancer Med"},{"issue":"8","key":"1530_CR90","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s13258-023-01412-7","volume":"45","author":"H Zhou","year":"2023","unstructured":"Zhou H, Liu H, Li J, Wang J, Fu X, Li Y, et al. Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer. Genes Genomics. 2023;45(8):1037\u201346.","journal-title":"Genes Genomics"},{"issue":"3","key":"1530_CR91","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.esmoop.2022.100452","volume":"7","author":"VF Bonazzi","year":"2022","unstructured":"Bonazzi VF, Aoude LG, Brosda S, Lonie JM, Patel K, Bradford JJ, et al. ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open. 2022;7(3):100452.","journal-title":"ESMO Open"},{"key":"1530_CR92","doi-asserted-by":"crossref","unstructured":"Richter F, Henssen C, Steiert TA, Meissner T, Mehdorn AS, R\u00f6cken C et al. Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer. Int J Mol Sci. 2023;24(13).","DOI":"10.3390\/ijms241310673"},{"issue":"5","key":"1530_CR93","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41419-020-2531-z","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis. 2020;11(5):346.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1530_CR94","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","volume":"158","author":"TD Azad","year":"2020","unstructured":"Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, et al. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology. 2020;158(3):494\u2013e5056.","journal-title":"Gastroenterology"},{"issue":"11","key":"1530_CR95","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1002\/ctm2.1116","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, Yu N, Cheng G, Zhang T, Wang J, Deng L, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Clin Transl Med. 2022;12(11):e1116.","journal-title":"Clin Transl Med"},{"issue":"1","key":"1530_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/clinchem\/hvad188","volume":"70","author":"Z Allan","year":"2024","unstructured":"Allan Z, Liu DS, Lee MM, Tie J, Clemons NJ. A Practical Approach to Interpreting Circulating Tumor DNA in the Management of Gastrointestinal Cancers. Clin Chem. 2024;70(1):49\u201359.","journal-title":"Clin Chem"},{"issue":"1","key":"1530_CR97","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1038\/s41598-024-54361-w","volume":"14","author":"W Li","year":"2024","unstructured":"Li W, Huang X, Patel R, Schleifman E, Fu S, Shames DS, et al. Analytical evaluation of circulating tumor DNA sequencing assays. Sci Rep. 2024;14(1):4973.","journal-title":"Sci Rep"},{"issue":"8","key":"1530_CR98","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/1878-0261.12729","volume":"14","author":"TV Henriksen","year":"2020","unstructured":"Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtr\u00f6der K, G\u00f6genur M, et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Mol Oncol. 2020;14(8):1670\u20139.","journal-title":"Mol Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01530-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:02:10Z","timestamp":1784653330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01530-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01530-x","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this study declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study discusses the current developments within the field of genomic ctDNA analysis in gastroesophageal cancers, the authors have determined that an ethical approval is not required.","order":3,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"160"}}